Teva’s chief drug Austedo—approved in Huntington’s disease and tardive dyskinesia—grew sales 19% to $498 million for the ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net ...

Takeda, coming off a high of 2024 growth, is pushing through what it says will be the worst of its Vyvanse-related declines.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a ...

Teva (TEVA) stock in focus as the company posts mixed Q2 2025 results amid its underperforming generic drugs. Read more here.

In this week’s edition of InnovationRx, we look at Halle Berry’s menopause startup, Ambience Healthcare’s $243 million ...

Teva anticipates EBITDA recovery post-2025 as Austedo and Uzedy grow and generic Revlimid faces rising competition.

From the Analyst's Couch Published: December 2005 Authorized Generics Gregory Glass Nature Reviews Drug Discovery 4, 953–955 (2005) Cite this article ...

Sun Pharmaceutical Industries Ltd. settled claims worth $200 million in an antitrust case in Pennsylvania alleging that the ...

Wockhardt announces its exit from the US generics market, shifting focus to its innovative antibiotic and biologicals ...

As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...

Srivastava noted that India’s major exports to the US include pharmaceuticals and petroleum products. For the pharmaceutical ...